Diabetic Neuropathy Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

(Albany, USA) DelveInsight's, "Diabetic Neuropathy Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Diabetic Neuropathy Research. Learn more about our innovative pipeline today! @ Diabetic Neuropathy Pipeline Outlook- https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Diabetic Neuropathy Pipeline Report
• In December 2024:- Eurofarma Laboratorios S.A.- A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy.
• In December 2024:- Vertex Pharmaceuticals Incorporated- A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
• DelveInsight's Diabetic Neuropathy pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Diabetic Neuropathy treatment.
• The leading Diabetic Neuropathy Companies such as Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Inc., Teijin America, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, ChemoCentryx, Roche, Cyclerion Therapeutics, Inversago Pharma Inc, Sunshine Lake Pharma Co., Ltd., Goldfinch Bio, Cosette Pharmaceuticals, Boehringer Ingelheim, Chinook Therapeutics, and others.
• Promising Diabetic Neuropathy Therapies such as Incobotulinumtoxin-A 100 UNIT Injection, Saline, LY3556050, N0750, and others.

Stay informed about the cutting-edge advancements in Diabetic Neuropathy treatments. Download for updates and be a part of the revolution in care @ Diabetic Neuropathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Diabetic Neuropathy Overview
Diabetic neuropathy is a type of nerve damage caused by prolonged high blood sugar levels in people with diabetes. It affects various nerves in the body, leading to symptoms such as pain, tingling, numbness, and muscle weakness, primarily in the hands and feet. The condition is classified into four main types: peripheral, autonomic, proximal, and focal neuropathy, each affecting different nerve groups.

Peripheral neuropathy is the most common form, primarily impacting the extremities. Autonomic neuropathy affects involuntary functions like digestion, heart rate, and bladder control. Proximal neuropathy leads to muscle weakness, especially in the hips and thighs, while focal neuropathy results in sudden nerve damage, often affecting specific nerves in the head, torso, or limbs.

Risk factors include poor blood sugar control, long-term diabetes, obesity, smoking, and high blood pressure. Managing diabetic neuropathy involves blood sugar regulation, pain management through medications, physical therapy, and lifestyle modifications like a balanced diet, regular exercise, and avoiding smoking or alcohol. Early diagnosis and preventive measures can help slow its progression and reduce complications such as foot ulcers, infections, and mobility issues. Regular screenings and diabetic care are crucial for minimizing nerve damage and improving quality of life.

Diabetic Neuropathy Emerging Drugs Profile
• SER 150: Serodus
SER150 is an anti-inflammatory compound with a novel mode of action both inhibiting thromboxane synthase as well as blocking the thromboxane (TP) receptor. SER150 is expected to specifically inhibit the inflammatory processes in the renal arterioles and glomeruli and reduce the progression of renal impairment whereby the amount of protein excreted in urine will decrease. Treatment with ACE-inhibitor antihypertensives is the golden standard of treatment of diabetic nephropathy but that treatment does not inhibit the fundamental causes of renal damage nor does it cure the disease. Since the inflammation is a progressive process causing loss of the renal function, SER150 could potentially become a very significant combination (add-on) therapy as standard daily treatment in patients with diabetic nephropathy. It is expected that SER150 treatment delays progression or even prevents development of the disease. Consequently, SER150 has a blockbuster market potential. Currently, the drug is in Phase II/III stage of its development for the treatment of diabetic neuropathy.

• LMB-763: Novartis
Nidufexor is a novel investigational compound with partial FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo. Nidufexor has advanced to Phase II human clinical trials in patients with NASH and diabetic nephropathy. The drug candidate is farnesoid X-activated receptor agonists. Currently, the drug is in Phase II stage of its development for the treatment of diabetic neuropathy.

• CU01: Curacle Co., Ltd
CU01 Dimethyl fumarate (DMF). CU01 has excellent therapeutic effects in reducing renal fibrosis by activating Nrf2 to inhibit TGF-β/SMAD signaling and the expression of extracellular matrix. The drug candidate is applicable only for early symptom relief. Not applicable to patients with ESRD (End Stage Renal Disease).There is an unmet medical need for cardiovascular protection agents. Currently, the drug is in Phase II stage of its development for the treatment of diabetic neuropathy.

Learn more about Diabetic Neuropathy Drugs opportunities in our groundbreaking Diabetic Neuropathy Research and development projects @ Diabetic Neuropathy Unmet Needs- https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Diabetic Neuropathy Companies
Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Inc., Teijin America, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, ChemoCentryx, Roche, Cyclerion Therapeutics, Inversago Pharma Inc, Sunshine Lake Pharma Co., Ltd., Goldfinch Bio, Cosette Pharmaceuticals, Boehringer Ingelheim, Chinook Therapeutics, and others.

Diabetic Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Diabetic Neuropathy Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Diabetic Neuropathy treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Diabetic Neuropathy Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Diabetic Neuropathy Pipeline Report
• Coverage- Global
• Diabetic Neuropathy Companies- Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Inc., Teijin America, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, ChemoCentryx, Roche, Cyclerion Therapeutics, Inversago Pharma Inc, Sunshine Lake Pharma Co., Ltd., Goldfinch Bio, Cosette Pharmaceuticals, Boehringer Ingelheim, Chinook Therapeutics, and others.
• Diabetic Neuropathy Therapies- Incobotulinumtoxin-A 100 UNIT Injection, Saline, LY3556050, N0750, and others.
• Diabetic Neuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diabetic Neuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Diabetic Neuropathy Pipeline on our website @ Diabetic Neuropathy Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Diabetic Neuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Neuropathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II/III)
11. SER 150: Serodus
12. Drug profiles in the detailed report.....
13. Early Stage Products
14. Drug name : Company name
15. Drug profiles in the detailed report.....
16. Inactive Products
17. Diabetic Neuropathy Key Companies
18. Diabetic Neuropathy Key Products
19. Diabetic Neuropathy- Unmet Needs
20. Diabetic Neuropathy- Market Drivers and Barriers
21. Diabetic Neuropathy- Future Perspectives and Conclusion
22. Diabetic Neuropathy Analyst Views
23. Diabetic Neuropathy Key Companies
24. Appendix

Trending Reports:
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.